| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000013599 |
| Receipt No. | R000015885 |
| Official scientific title of the study | Diagnosis of chronic cough on the basis of FeNO and response to the therapy |
| Date of disclosure of the study information | 2014/04/01 |
| Last modified on | 2016/04/01 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Diagnosis of chronic cough on the basis of FeNO and response to the therapy | |
| Title of the study (Brief title) | Diagnosis of chronic cough on the basis of response to the therapy | |
| Region |
|
|
| Condition | ||
| Condition | Patients with prolonged or chronic cough | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | Trial for making diagnosis of proronged or chronic cough by response to the therapy on the basis of FeNO |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Explanatory |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Effect of H1 blocker or combination of ICS and LABA on cough as a primary therapy |
| Key secondary outcomes | |
| In outcomes field, the entry of just a few words such as "safety" or "efficiency" will not be accepted. Specify the name of outcome measures, including the time when you plan to measure. Usually, only one primary outcome is accepted. Write the other outcomes in "secondary outcomes" field. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Diagnosis | |
| Type of intervention |
|
|
| Interventions/Control_1 | H1 blocker or ICS/LABA | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| In interventions field, include the details of interventions, such as duration, amount, and frequency. If the intervention includes prescription or use of medical devices, duration is required. |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients whose cough comtinues more than 3 weeks | |||
| Key exclusion criteria | Patients with apparent productive cough
Respiratory infection required abtibiotics Abnormal chest X-ray causing cough Patients who do not consent to the trial |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Tamotsu Ishizuka |
| Organization | Faculty of Medical Sciences, University of Fukui |
| Division name | Third Department of Internal Medicine |
| Address | 23-3 Matsuoka-Shimoaizuki, Eiheiji-cho, Yoshida-gun. Fukui 910-1193 |
| TEL | 0776-61-8355 |
| tamotsui@u-fukui.ac.jp | |
| Public contact | |
| Name of contact person | Tamotsu Ishizuka |
| Organization | Faculty of Medical Sciences, University of Fukui |
| Division name | Third Department of Internal Medicine |
| Address | 23-3 Matsuoka-Shimoaizuki, Eiheiji-cho, Yoshida-gun, Fukui 910-1193 |
| TEL | 0776-61-8355 |
| Homepage URL | |
| tamotsui@u-fukui.ac.jp | |
| Sponsor | |
| Institute | Third Department of Internal Medicine, FAculty of Medical Sciences, University of Fukui |
| Institute | |
| Department | |
| Sponsor means an organization that is responsible for plan, deployment and report of the research including funding management. It doesn't mean funding agency". Therefore, all clinical trial should have the one. |
| Funding Source | |
| Organization | Third Department of Internal Medicine, FAculty of Medical Sciences, University of Fukui |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-bin/icdr_e/ctr_view.cgi?recptno=R000015885 |